Mint Tower Capital Management B.V. Buys Shares of 250,000 Drugs Made In America Acquisition II Corp. $DMII

Mint Tower Capital Management B.V. bought a new stake in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 250,000 shares of the company’s stock, valued at approximately $2,475,000.

Several other large investors have also recently bought and sold shares of DMII. Geode Capital Management LLC bought a new position in shares of Drugs Made In America Acquisition II during the fourth quarter valued at $265,000. ABC Arbitrage SA bought a new position in shares of Drugs Made In America Acquisition II during the fourth quarter valued at $396,000. Deltec Asset Management LLC bought a new position in shares of Drugs Made In America Acquisition II during the fourth quarter valued at $495,000. Periscope Capital Inc. bought a new position in shares of Drugs Made In America Acquisition II during the fourth quarter valued at $2,628,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new position in shares of Drugs Made In America Acquisition II during the fourth quarter valued at $3,960,000.

Drugs Made In America Acquisition II Stock Down 0.0%

Shares of DMII stock opened at $10.09 on Friday. The business has a 50 day simple moving average of $10.03. Drugs Made In America Acquisition II Corp. has a fifty-two week low of $9.86 and a fifty-two week high of $10.09.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on DMII. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Drugs Made In America Acquisition II in a research note on Friday, May 29th. Wall Street Zen upgraded Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Drugs Made In America Acquisition II presently has an average rating of “Sell”.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.